Immunogenicity of Influenza Vaccine in Colorectal Cancer Patients
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose Although influenza is regarded as a major cause of morbidity and mortality in immunocompromised patients, vaccine coverage remains poor. We evaluated the immunogenicity of influenza vaccines in colorectal cancer patients. Materials and Methods In this study, 40 colorectal cancer patients who received an influenza vaccine at the Korea Cancer Center Hospital during the 2009-2010 and 2010-2011 influenza seasons were analyzed. The blood samples were collected at prevaccination and 30days post vaccination, and antibody titers were measured using the hemagglutination-inhibition tests. Results In the 2009-2011 season, the seroprotection rate for H1N1 (94.7%) was significantly higher than that for H3N2 (42.1%) and B (47.3%). The seroconversion rate was 52.6%, 26.3%, and 36.8% for H1N1, H3N2, and B, respectively. Fold increase of geometric mean titer (MFI) was 3.86, 1.49, and 3.33 for H1N1, H3N2, and B, respectively. In the 2010-2011 season, the seroprotection rate for H1N1 (57.1%) was significantly higher than that for H3N2 (52.4%) and B (38.1%). The seroconversion rate was 52.4%, 47.6% and 33.3% for H1N1, H3N2, and B, respectively. MFI was 12.29,3.62 and 4.27 for H1N1, H3N2, and B, respectively. Conclusion Our study cohort showed an acceptable immune response to an influenza vaccine without significant adverse effects, supporting the recommendation for annual influenza vaccination in colorectal cancer patients.
Abstract
Purpose Although influenza is regarded as a major cause of morbidity and mortality in immunocompromised patients, vaccine coverage remains poor. We evaluated the immunogenicity of influenza vaccines in colorectal cancer patients. Materials and Methods In this study, 40 colorectal cancer patients who received an influenza vaccine at the Korea Cancer Center Hospital during the 2009-2010 and 2010-2011 influenza seasons were analyzed. The blood samples were collected at prevaccination and 30days post vaccination, and antibody titers were measured using the hemagglutination-inhibition tests. Results In the 2009-2011 season, the seroprotection rate for H1N1 (94.7%) was significantly higher than that for H3N2 (42.1%) and B (47.3%). The seroconversion rate was 52.6%, 26.3%, and 36.8% for H1N1, H3N2, and B, respectively. Fold increase of geometric mean titer (MFI) was 3.86, 1.49, and 3.33 for H1N1, H3N2, and B, respectively. In the 2010-2011 season, the seroprotection rate for H1N1 (57.1%) was significantly higher than that for H3N2 (52.4%) and B (38.1%). The seroconversion rate was 52.4%, 47.6% and 33.3% for H1N1, H3N2, and B, respectively. MFI was 12.29,3.62 and 4.27 for H1N1, H3N2, and B, respectively. Conclusion Our study cohort showed an acceptable immune response to an influenza vaccine without significant adverse effects, supporting the recommendation for annual influenza vaccination in colorectal cancer patients.
참고문헌 (19)
- Whitley RJ, "Prevention and treatment of influenza in high-risk groups: children, pregnant women, immunocompromised hosts, and nursing home residents", J Infect Dis, 194(Suppl 2), pp.S133~S138 (2006)
- Ljungman P, "Influenza A in immunocompromised patients", Clin Infect Dis, 17, pp.244~247 (1993)
- Kumar D, "Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study", Lancet Infect Dis, 10, pp.521~526 (2010)
- Kunisaki KM, "Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses", Lancet Infect Dis, 9, pp.493~504 (2009)
- Beck CR, "Influenza vaccination for immunocompromised patients: systematic review and meta-analysis from a public health policy perspective", PLoS One, 6, pp.e29249~ (2011)
- Cho BH, "Influenza vaccination coverage rate among high-risk children during the 2002-2003 influenza season", Am J Infect Control, 36, pp.582~587 (2008)
- Meidani M, "Why coverage of influenza vaccine is not enough in patients receiving chemotherapy", Int J Prev Med, 2, pp.186~187 (2011)
- Muller D, "Influenza vaccination coverage rates in the UK: a comparison of two monitoring methods during the 2002-2003 and 2003-2004 seasons", Public Health, 120, pp.1074~1080 (2006)
- Earle CC, "Influenza vaccination in elderly patients with advanced colorectal cancer", J Clin Oncol, 21, pp.1161~1166 (2003)
- Loulergue P, "Low influenza vaccination rate among patients receiving chemotherapy for cancer", Ann Oncol, 19, pp.1658~ (2008)
- Kyu-Won Jung, "Prediction of Cancer Incidence and Mortality in Korea, 2012", Cancer Research and Treatment, 44(1), pp.15~31 (2012), 대한암학회
- "Committee for Proprietary Medicinal Products (CPMP). Note for guidance on harmonisation of requirements for influenza vaccines (CPMP", BWP, 96), pp.European Agency for the Evaluation of Medicinal Products, 1997[DOI]
- Puthillath A, "Serological immune responses to influenza vaccine in patients with colorectal cancer", Cancer Chemother Pharmacol, 67, pp.111~115 (2011)
- Anderson H, "Seroconversion after influenza vaccination in patients with lung cancer", Br J Cancer, 80, pp.219~220 (1999)
- Mazza JJ, "Efficacy of the influenza vaccine in patients with malignant lymphoma", Clin Med Res, 3, pp.214~220 (2005)
- Looijmans-Van den Akker I, "Clinical effectiveness of first and repeat influenza vaccination in adult and elderly diabetic patients", Diabetes Care, 29, pp.1771~1776 (2006)
- Xie H, "Immunogenicity and cross-reactivity of 2009-2010 inactivated seasonal influenza vaccine in US adults and elderly", PLos One, 6, pp.e16650~ (2011)
- Schafer AI, "The influence of chemotherapy on response of patients with hematologic malignancies to influenza vaccine", Cancer, 43, pp.25~30 (1979)
- Sambhara S, "Immunosenescence and influenza vaccine efficacy", Curr Top Microbiol Immunol, 333, pp.413~429 (2009)